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Dendritic cells are excellent targets for antigen-speci¢c
immune intervention. Here we attempted to introduce
a CD8 T cell-dependent epitope into dendritic cells for
presentation on major histocompatibility complex class
I and induction of immunity. Murine bone-marrow-de-
rived dendritic cells were subjected to electroporation
with mRNA transcribed in vitro from a plasmid encod-
ing lymphocytic choriomeningitis virus glycoprotein
or enhanced green £uorescent protein under the control
of a T7 promotor. The transfection e⁄ciency of dendri-
tic cells was 22 to 40%. Maturation was not inhibited by
the electroporation. Dendritic cells electroporated with
the appropriate antigen induced cell number-dependent
in vitro proliferation in CD8 T cells expressing a trans-
genic receptor recognizing the 33 to 41 sequence
of lymphocytic choriomeningitis virus glycoprotein in
association with H-2Kb/Db, indicating correct synthe-
sis, processing, and presentation of the epitope. Na|« ve
C57BL/6 mice vaccinated with electroporated dendritic
cells and challenged with lymphocytic choriomeningi-
tis virus were protected. Vaccination induced epitope-
speci¢c Tcells as assessed by tetramer staining in blood
and spleen. These results indicate that targeting dendri-
tic cells with antigen-encoding mRNA can induce anti-
gen-speci¢c CD8 T cell responses as well as protective
anti-viral immunity in vivo. Targeting dendritic cells
with antigen-encoding mRNA may ¢nd wider appli-
cation for immune intervention in disorders such as
autoimmunity and cancer. Key words: CD8 Tcells/dendri-
tic cells/lymphocytic choriomeningitis virus/mRNA transfec-
tion. J Invest Dermatol 121:745 ^750, 2003
D
endritic cells (DC) are crucial in the activation of
na|«ve T lymphocytes and induction of T lympho-
cyte-dependent immune responses (Banchereau
and Steinman, 1998; Jung et al, 2002). For this rea-
son, experimental modi¢cation of DC, in particu-
lar genetic antigen delivery, has attracted much interest. Adaptive
cell-mediated immunity may depend on either CD4 Tcells, CD8
Tcells or both.Whereas delivery of exogenous antigen to DC and
activation of CD4 Tcells did not present a technical problem, the
targeting of antigen for activation of CD8 T cells has been more
challenging. Synthetic CD8 epitopes can be loaded to DC by
simple incubation resulting in e⁄cient loading of major histo-
compatibility complex (MHC) class I molecules and stimulation
of CD8 T cells. The downside of this approach includes the re-
quirement of previous identi¢cation of MHC-restricted epitopes.
Further, loading of DC with a large amount of peptide corre-
sponding to the MHC-restricted epitope may induce low avidity
T cells that may not recognize the low physiologic amounts of
naturally processed antigen on target cells and consequently lead
to an ine⁄cient immune response (Rees et al, 1999; Jenne et al,
2000). DC can present antigen on MHC class I molecules to
CD8 T cells when it is synthesized in the cytoplasm as are viral
gene products. Thus, viral vectors such as adenoviral or lentiviral
constructs have successfully been employed to deliver MHC class
I restricted antigenic epitopes to DC (Monahan and Salgaller,
1999; Song et al, 2000; Dyall et al, 2001; Zarei et al, 2002). The
downside of this approach includes induction of immunity to
the viral vector and incorporation of viral material into host cells.
Presentation of exogenous antigen on MHC class I has been
described in DC and is referred to as cross-presentation. Thus,
the loading of DC with exogenous antigen may represent an-
other approach.The e⁄ciency of cross-presentation for the induc-
tion of protective immunity, however, remains controversial
(Ochsenbein et al, 2001). Coating of antigen to microparticles en-
ables DC to phagocytize and present antigen on MHC class I
(Kovacsovics-Bankowski et al, 1993; Shen et al, 1997). Several me-
chanisms in DC may enhance the e⁄ciency of cross-presentation.
Examples include the delivery of antigen to DC via antibodies
and Fc receptors (Amigorena, 2002) or via coupling to some heat
shock proteins (Li et al, 2002) or bacterial toxins such as the Kleb-
siella pneumoniae outer membrane protein A (Jeannin et al, 2000).
Transfection of DC with antigen-encoding plasmid has been de-
scribed but the transfection e⁄ciency is usually low. Finally, elec-
troporation of DC with antigen-encoding mRNA is promising.
This method produced a signi¢cantly higher transfection e⁄-
ciency than transfection with plasmid in a recent report (Van
Meirvenne et al, 2002).
In this study we asked the question whether electroporation of
DC with antigen-encoding mRNA can be employed to induce
protective MHC class I and CD8-dependent immunity. As
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expression of lymphocytic choriomeningitis virus (LCMV) gly-
coprotein in transfected DC may not become detectable with
standard immunologic methods we established optimal electro-
poration conditions with mRNA encoding enhanced green
£uorescent protein (EGFP).We used LCMV as a model for non-
T-cell-cytopathic virus infection. In this model, viral protection
is CD8 and perforin dependent (Kagi et al, 1996; Ehl et al, 1997).
In addition, the availability of a transgenic mouse strain with a T
cell receptor recognizing the protective epitope (amino acid posi-
tions 33^41) of LCMV glycoprotein in association with MHC
class I (KbDb) permitted a direct in vitro readout for appropriate
antigen presentation (Ohashi et al, 1991).
MATERIALS AND METHODS
Peptide, antibodies, and mice Synthetic peptide (KAVYNFATM)
corresponding to amino acids 33 to 41 of the LCMV glycoprotein in
which C was replaced by M in position 41 (Kyburz et al, 1993; Kundig
et al, 1995) was purchased from Neosystem (Strasbourg, France). Purity
wasX 75% as assessed by high-performance liquid chromatography.
Allophycocyanin-labeled streptavidin and the following phycoerythrin-
conjugated monoclonal antibodies (MoAb) were purchased from BD
Pharmingen (San Diego, California): anti-CD11c (hamster IgG, clone
HL3) and isotype control (hamster IgG, clone A19-3). Biotin-labeled
MoAb included anti-MHC class II (I-A/I-E, rat IgG2a, clone 2G9), anti-
CD40 (rat IgG2a, clone 3/23), anti-CD80 (hamster IgG, clone 16-A10A1),
anti-CD86 (rat IgG2a, clone GL1), and isotype controls (hamster IgG,
clone B81-8; rat IgG2a, clone R35^95). Fluorescein isothiocyanate labeled
anti-CD8a (rat IgG2a, clone 53-6-7).
Female or male C57BL/6 mice were purchased from IFFA-Credo
(L’Arbresle, France) and were used between 6 and 12 wk of age. Transgenic
mice (line 327) expressing the transgenic P14 T cell receptor (C57BL/6,
Va2b8) speci¢c for H-2Db and Kb restricted LCMVglycoprotein 33 to 41
have previously been described (Ohashi et al, 1991). These mice express
the transgenic receptor on approximately 90% of their CD8þ T
cells. Transgenic mice were kindly provided by Drs R.M. Zinkernagel
and H. Hengartner (Institute of Experimental Immunology, Zurich,
Switzerland). All mice were maintained under speci¢c pathogen-free
conditions. Institutional and the Geneva state’s approval for the animal
experiments in this report was obtained.
In vitro transcription of LCMV and EGFP mRNA To generate
in vitro transcribed EGFP and LCMVmRNA, the vectors pcDNA3.1/EGFP/
A71 and pcDNA3.1/LCMV/A71 were constructed. Oligodeoxynucleotides
containing 71 A-T bp followed by a MluI restriction site were purchased
from MWG Biotech (Ebersberg, Germany) (forward 50^30: TAGC(A)71
CGCGT; reverse 50^30: GCTAACGCG(T)71). Equimolar amounts of
oligodeoxynucleotides were annealed and cloned into the BbsI site of
pcDNA3.1(þ ) (Invitrogen, San Diego, California) to create the plasmid
pcDNA3.1/A71. A 1571 bp BamHI fragment containing the entire coding
sequence for LCMV was isolated from pKooL/LCMV (kind gift of
Dr Zinkernagel) and was ligated into the BamHI site of pcDNA3.1/A71
to generate the plasmid pcDNA3.1/LCMV/A71. Annealed oligod-
eoxynucleotides were also ligated into the BbsI site of pcDNA3.1/EGFP
(Invitrogen) to create the plasmid pcDNA3.1/EGFP/A71. pcDNA3.1/LCMV/
A71 and pcDNA3.1/EGFP/A71 plasmids were linearized with MluI,
puri¢ed using QIAquick puri¢cation Kit (Qiagen, Basel, Switzerland),
and used as DNA templates for in vitro transcription reaction. One
microgram of cDNA was placed in a standard in vitro transcription
reaction using a T7 mMessage mMachine Kit (Ambion, Austin, Texas) at
371C for 3 to 4 h. RNA puri¢cation was performed by DNase I digestion
followed by lithium chloride precipitation and 70% ethanol wash,
according to the manufacturer’s instructions. The mRNA pellet was
resuspended in RNase free water, and the quantity and purity of in vitro
transcribed mRNA were determined by ultraviolet spectrophotometry.
An aliquot was electrophoresed on an agarose/formaldehyde gel to
determine integrity and size range of the RNA products.
DC preparation and transfection Bone-marrow-derived DC were
generated as published previously (Young et al, 1989; Kundig et al, 1995;
Jung et al, 2002). Brie£y, femora and tibiae of 6 to 12 wk old C57BL/6
mice were £ushed with 3 to 5 mL of DC medium (Iscove’s modi¢ed
Dulbecco’s medium, supplemented with 100 mg streptomycin per mL, 100
U per mL penicillin, and 2 mM L-glutamine, 10% heat-inactivated fetal
bovine serum (all from Life Technologies, Switzerland) and 2105 M
2-mercaptoethanol (Sigma, St Louis, Missouri). Particulate matter was
¢ltered and the red blood cells were lyzed. Bone marrow cells were
seeded with a density of 106 cells per well in six well culture plates. Bone
marrow cells were di¡erentiated into DC by culturing in 3 mL of DC
media supplemented with 25 ng per mL of recombinant murine
granulocyte/macrophage-colony stimulating factor (ImmunoKontact,
Lugano, Switzerland), 1000 U per mL of recombinant murine interleukin-
4 supernatant of X63/O transfectant (Kyburz et al, 1993) and 10 ng per mL
of recombinant murine FMS-related tyrosine kinase 3 ligand (Flt3-L)
(R&D, Abingdon, UK) for 9 d. At days 2, 4, and 6, the adherent cells
received fresh medium and growth factors. DC cells were harvested at
day 7, washed twice with serum-free RPMI and resuspended to a ¢nal
concentration of 4106 cells per mL in Opti-MEM medium (Life
Technologies, Basel, Switzerland). Subsequently, 0.5 mL cell suspension
was mixed with 100 mg mRNA and electroporated in a 0.4 cm cuvette
(voltage: 0.26 kV, capacitance: 960 mF) using the Gene Pulser System
(Biorad, Hercules, California). After electroporation, DC were matured by
adding 1 mg lipopolysaccharide per mL (LPS, Difco, Detroit, Michigan) in
the presence of cytokines. After 48 h, nonadherent cells were harvested and
used for various assays.
Flow cytometric analysis Cells were incubated with the indicated
antibodies and were analyzed on a FACSCalibur cytometer (Becton
Dickinson, Mountain View, California). Living cells were identi¢ed by
means of the nonpermeant DNA dye 7-amino-actinomycin D (Sigma).
Data were analyzed with WINMDI software written by J. Trotter
(Scripps, La Jolla, California) and Cell-Quest software (Becton
Dickinson). A minimum of 104 cells were analyzed for each sample.
Flow cytometric analysis by tetrameric class I^peptide complexes
H2-Db/GP33-41 (KAVYNFATM) tetramer coupled to phycoerythrink
(PE) was provided by the Tetramer Facility of the National Institute of
Allergy and Infectious diseases (NIAID) of the National Institute of
Health (NIH,Washington). Mice were received intravenous 0.5106 DC
transfected with LCMV or green £uorescent protein encoding mRNA,
0.5105 DC pulsed with 107 M LCMV glycoprotein peptide or 200
plaque forming units (PFU) of LCMV (WE strain). After 8 d, all groups
of mice, except mice infected with LCMV, were challenged with 200 PFU
LCMV (WE strain). Five days after challenge, mice were bled and
euthanized. Peripheral blood mononuclear cells or spleen cells were
isolated. Cells were recovered after Ficoll-Paque (Pharmacia, Uppsala,
Sweden) gradient centrifugation, washed twice with phosphate-bu¡ered
saline containing 2% fetal bovine serum and 0.1% NaN3 and incubated
with MoAb to Fcg receptor (2.4G2; American Type Culture Collection,
Manassas, Virginia) prior to staining with £uorescein isothiocyanate
coupled anti-CD8a and tetramer PE. Cells were washed after 40 min,
and analyzed in a FACScan cytometer. A minimum of 3 to 4104 cells
were analyzed for each condition.
T cell proliferation assay Nylon wool ¢ltered and MHC class II and
CD4-depleted spleen and lymph node cells (90% CD8þ ) of naive
transgenic mice were incubated in 96-well plates (0.5105 cells per well)
with DC. Culture media consisted of DMEM containing 10% heat
inactivated fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate,
1% nonessential amino acids 100 U per mL penicillin, 100 mg
streptomycin per mL (all Life Technologies), and 2105 M 2-
mercaptoethanol (Sigma). LPS-matured DC previously electroporated or
pulsed with 107 M LCMV peptide were added at various cell numbers. T
cell proliferation after 3 d was assessed by incorporation of radioactive
thymidine.
Viral protection assay C57/BL6 recipient mice were immunized twice
intravenously with DC electroporated with LCMV glycoprotein mRNA
or EGFP mRNA in a weekly interval. Mice were subsequently infected
with 200 PFU LCMV (WE strain) 8 d after the last immunization. Five
days after immunization, mice were euthanized and the virus titer was
determined in the spleen by an immunologic focus-forming assay
(Battegay et al, 1991). Brie£y, spleens were homogenized in glass tubes
and spun at 1700 g for 10 min at 41C. Serial 10-fold dilutions of
homogenized supernatants were incubated with the adherent ¢bro-
sarcoma cell line MC57G in 24-well plates. After adsorption of virus by
cells and 48 h culture under a methylcellulose overlay, monolayers were
¢xed, permeabilized, and stained with a rat MoAb to LCMV (VL-4)
(Battegay et al, 1991), a peroxidase-labeled second-step antibody, and
tetramethylbenzidine/4 -chloronaphtol as chromogens (both from Fluka,
Buchs, Switzerland).Virus titers are expressed as PFU per g tissue.
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RESULTS AND DISCUSSION
Electroporation of DC with mRNA permits the expression
of the transgene Bone-marrow-derived murine DC cultured in
granulocyte/macrophage-colony stimulating factor, interleukin-
4, and Flt3-L were subjected to electroporation with mRNA
encoding EGFP under di¡erent voltage and capacitance
conditions and analyzed 24 h later by £ow cytometry. In our
hands, the use of 260 mV and 960 mF yielded in optimal
conditions with regard to transfection e⁄ciency and cell
viability. The optimal amount of mRNA per condition was 100
mg. Average transfection e⁄ciency was 29.2% (22^39.5%, ¢ve
experiments, Fig 1). These values are lower than those reported
by Van Meirvenne et al (2002) who achieved a 70% transfection
e⁄ciency with lower amounts of mRNA. This may be related
to di¡erent electroporation conditions and equipment. Electro-
poration of DC did not a¡ect signi¢cantly the cell recovery at
optimal in-house conditions when compared with nonelectro-
porated DC (data not shown). Similar to the experience of other
groups, passive transfection, a method pioneered by the group in
Gilboa (Nair et al, 1998), was not successful in our hands (data not
shown). The results in Fig 1 also demonstrate that the majority of
cells carried the DC marker CD11c and expressed MHC class II.
Almost all EGFP-expressing cells were CD11cþ . Electroporation
with the corres-ponding plasmid DNA under identical conditions
resulted in high cell mortality (73%) and a low transfection
rate (1.6%).
DC maturation is not impaired by mRNA electropora-
tion In order to assess whether DC can mature after
electroporation, electroporated DC were incubated with LPS.
Twenty-four hours later, £ow cytometric analysis was
performed. The results in Fig 2 show that MHC class II, CD40,
CD80, and CD86 expression in EGFP expressing cells was
indistinguishable from nonelectroporated DC, demonstrating
that mRNA electroporation did not interfere negatively with
DC maturation. Regardless of electroporation and addition of
LPS, control DC had high surface expression of accessory
molecules (Fig 2) compared with DC left untouched for 8 d
(not shown), suggesting that the mechanical stress of cell
handling alone without electroporation or addition of LPS was
su⁄cient to mature murine bone-marrow-derived DC (Gallucci
et al, 1999). This contrasts our and other investigators experience
with human DC. LPS incubation increased CD40 and CD86
but not MHC class II and CD80 expression in electroporated
and nonelectroporated cells. Electroporation per se did not
further increase accessory molecule expression. This con¢rmed
the observation made byVan Meirvenne et al (2002).
mRNA electroporated DC activate antigen-speci¢c CD8þ
T cells in vitro Because translation of LCMV mRNA in DC
may permit T cell activation, we investigated whether DC
electroporated with mRNA encoding LCMV glycoprotein can
activate antigen-speci¢c T cells. Thus, DC were incubated with
CD8 T cells from transgenic mice expressing a T cell receptor
speci¢c for LCMV glycoprotein positions 33 to 41 and the b
haplotype of MHC class I (KbDb). Proliferation of transgenic
CD8 T cells was dependent on the number of DC transfected
with the relevant mRNA (Fig 3). The stimulatory capacity was
similar to DC pulsed with an optimal concentration of LCMV
glycoprotein peptide 33 to 41, assuming a 20% transfection
e⁄ciency. The magnitude of the proliferative response was simi-
lar to DC pulsed with an optimal amount of LCMV peptide
(41010 M). The T cell response was speci¢c for the mRNA
transfected as EGFP-transfected cells had the same background
proliferation as nontreated DC incubated with T cells. Together,
these results demonstrate appropriate and e⁄cient processing
and presentation of LCMVglycoprotein translated from electro-
porated mRNA. LCMV glycoprotein processing has previously
been shown to be dependent on transporter associated with anti-
gen presentation (TAP) (Hombach et al, 1995).We have recently
shown that LCMV glycoprotein introduced into DC by a lenti-
viral construct used TAP for e⁄cient presentation (Zarei et al,
2002). Unlike Van Meirvenne et al (2002), we did not use
ubiquitination sequences to direct antigen for degradation by the
proteasome complex and subsequent MHC class I presentation.
Figure1. Flow cytometric analysis of transgene expression in murine DC following EGFP mRNA transfection. Murine DC were electropo-
rated with mRNA encoding EGFP and were analyzed after 24 h by £ow cytometry.Viability was determined by 7-amino-actinomycin D (7-AAD) stain-
ing. These results are representative of ¢ve independent experiments. MHCII, MHC class II.
MRNATRANSFECTED DENDRITIC CELLS 747VOL. 121, NO. 4 OCTOBER 2003
Figure 2. Electroporation of DC does not interfere with their maturation process. After transfection of DC with EGFP encoding mRNA, cells
were incubated with or without LPS. After 24 h, the expression of surface markers of transfected (EGFPþ ) and nontransfected DC from the same experi-
ment were analyzed by FACScalibur. Isotype controls are shown by dotted lines, immature DC are presented with ¢lled histograms, and LPS-treated cells
are represented by bold lines. These results are representative of ¢ve independent experiments. GFP, green £uorescent protein. MHCII, MHC class II.
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Figure 3. Transfected DC are able to present the LCMVglycoprotein to transgenic CD8 Tcells speci¢c for the 33 to 41 epitope. Transgenic T
cells (5104 cells per well) were incubated with graded numbers of DC transfected with LCMV glycoprotein mRNA (’), DC pulsed with 10^7 M
glycoprotein 33 to 41 peptide (&), or 5103 DC pulsed with di¡erent concentrations of glycoprotein 33 to 41 peptide ( ). DC/transgenic CD8 T cell
ratio 1:10. These results are representative of two independent experiments. gp, glycoprotein; tg, transgenic.
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We were not successful in detecting LCMV glycoprotein
expression by £ow cytometry. Hengartner et al were unable to
detect LCMV glycoprotein in pancreatic islet cells in animals
transgenic for LCMV glycoprotein under the control of the rat
insulin promotor by western blotting (personal communica-
tion). It is thus possible that the expression of LCMVglycoprotein
detectable by antibody is low in mammalian cells but su⁄cient for
T cell activation.
Vaccination with mRNA electroporated DC induces the
expansion of antigen-reactive T cells in vivo We next asked
whether in vivo administration of DC transfected with mRNA
encoding LCMV glycoprotein could cause accelerated expansion
of LCMVglycoprotein reactive CD8 T cells upon infection with
live LCMV. C57/BL6 mice received 5105 DC electroporated
with mRNA encoding either LCMV glycoprotein, 5104 DC
pulsed with LCMVglycoprotein peptide 33 to 41 or control DC.
One week later, mice were challenged with live LCMV. Five days
later, peripheral blood mononuclear cells and spleen cells were
stained with a MoAb to CD8 and to T cell receptors reactive
with tetramers consisting of MHC class I (H-2Db) and LCMV
glycoprotein peptide 33 to 41. LCMV mRNA induced a mean
of 1.25% and 1.12% tetramer-positive cells among CD8 T cells
in blood and spleen, respectively (see also Fig 4). EGFP mRNA
transfected DC induced a mean of 0.56% and 0.50% tetramer-
positive cells among CD8 T cells in blood and spleen,
respectively. Corresponding values for peptide pulsed DC were
2.37% and 3.03%, respectively, and for nonpulsed DC 0.50%
and 0.48%, respectively. Thus, transfected DC and peptide
pulsed DC induced enhanced proportions of tetramer-positive
cells among CD8 T cells in blood and spleen, which resolved
as clearly separate positive populations by £ow cytometry,
compared with near background staining in the control groups.
The administration of lower numbers of DC did not induce an
appreciable increase of double positive cells. Infection with live
LCMV, known to provide protection upon subsequent infection,
induced tetramer-positive cells among CD8 T cells in the 10%
range after 13 d. Vaccination with DC without subsequent live
LCMV challenge did not induce appreciable numbers of CD8þ
tetramer-positive cells (data not shown). These experiments
demonstrate that vaccination with DC either transfected with
LCMV glycoprotein or pulsed with glycoprotein 33 to 41
induces speci¢c CD8 T cells that are readily detectable by
tetramers ex vivo, although at a lower frequency than at 13 d
after infection with live virus.
Vaccination with mRNA-transfected DC provides protec-
tion against LCMV infection In order to test whether
transfected DC provide CD8-dependent protection against
LCMV, na|«ve mice were injected intravenously with DC twice
in a weekly interval and challenged with LCMV intravenously
1 wk later. Five days after challenge, the spleens were removed
and the LCMV titer determined in the splenic homogenate.
Mice receiving DC transfected with mRNA encoding LCMV
glycoprotein had splenic LCMV titers that were 4 logs lower
than mice that received DC with mRNA encoding an irrelevant
protein (EGFP) (Fig 5) or nontreated mice (data not shown).
This e¡ect was observed with DC numbers as low as 3104
(Fig 5). At 1.5104 DC transfected with LCMV glycoprotein
mRNA, most but not all animals were protected (not shown).
Assuming a 20% transfection e⁄ciency, 6 to 10103 DC were
su⁄cient to provide complete viral protection. Ludewig et al
(1999) required similar numbers of DC from mice transgenic for
LCMV glycoprotein for full protection, indicating that mRNA-
transfected cells were e⁄cient immunogens for CD8-dependent
immunity in this model. To our knowledge, successful DC
vaccination in an in vivo model with electroporated mRNA has
not been reported previously.
Figure 4. Immunization with DC electroporated with LCMVmRNA leads to expansion of antigen-speci¢c CD8þ Tcells as determined by
staining with MHC class I tetramers. Density plot of blood cells stained with glycoprotein 33 to 41 tetramer and CD8 from C57/BL6 mice immunized
under the indicated conditions and then challenged with LCMV WE. Peripheral blood mononuclear cells from mice infected with LCMV WE but not
challenged were stained with tetramer 13 d postinfection (200 PFU LCMVWE).The percentage of tetramer-positive cells among CD8þ Tcells is indicated
in each panel. Nonpulsed DC induced 0.29% tetramer-positive cells among CD8þ T cells. This experiment is representative of two independent experi-
ments. gp, glycoprotein.
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Figure 5. Protection of mice immunized with DC transfected
LCMV glycoprotein encoding mRNA. Mice were immunized twice
in weekly intervals with the indicated numbers of DC. One week later,
mice were challenged with 200 PFU LCMV (WE strain). Five days later,
LCMV titers were determined in the spleen. p¼ 0.05; PFU per g, PFU
per gram wet tissue. These results are representative of ¢ve independent
experiments. gp, glycoprotein.
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It is of note that the induction of in vivo protection is detected
more readily than tetramer-positive cells, as protection was
appreciable at much lower numbers of DC used for vaccination
(even after a single vaccination, data not shown) than were
necessary to expand tetramer-positive cells. This result is con-
sistent with ¢ndings of Pien et al (2002), who observed the induc-
tion of anti-viral defenses (particularly high levels of interferon-g
secreted by CD8 T cells) well before a signi¢cant expansion of
LCMV-speci¢c cytotoxic T cells was detectable by tetramers. It
may also re£ect the induction of protective T cells to other
epitopes than the 33 to 41 sequence of LCMV glycoprotein.
Overall, the data indicate that vaccine e⁄cacy is best assessed by
several readouts, as protection to LCMV challenge can be
achieved with even a modest expansion of speci¢c T cells.
In conclusion, we have shown that a cellular vaccine consisting
of DC transfected with antigen-encoding mRNA can provide
CD8-dependent viral protection in vivo. This transfection and
vaccination strategy may become applicable to other CD8
epitopes, including tumoral CD8 epitopes, that may confer
immune protection. Many tumor-associated antigens have been
sequenced and known to possess MHC class I epitopes. mRNA
possibly encoding multiple tumor antigens could be transfected
in vitro into DC derived from patients and then be used as a
cellular vaccine. Similarly, molecularly de¢ned targets of
autoimmune disease, such as desmoglein 3 in pemphigus
vulgaris, could be expressed in DC that mediate suppression in
vivo (regulatory DC) (Sato et al, 2003). Antigen expressing
regulatory DC may become useful for the induction of
suppression.
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